Group 1 - Tianfu and Nova Coffee are collaborating to promote a "convenience store + coffee" model, leveraging Nova's product strength and Tianfu's 7,500 convenience store channels to enhance operational efficiency and target younger consumers [1] - The China Securities Regulatory Commission has requested additional materials from Banou regarding its Hong Kong IPO application, focusing on key issues such as equity structure and compliance [3] - JD Group's CEO stated that the company will not participate in the "malicious subsidies" in the food delivery market, which he believes disrupts the pricing system and creates a lose-lose situation for all parties involved [4] Group 2 - Suning.com announced a debt settlement with Carrefour, planning to pay 220 million yuan to clear related debts, which will result in Suning indirectly holding 100% of Carrefour China [6] - Guizhou Moutai reported a net profit of 45.403 billion yuan for the first half of 2025, with a revenue of 89.389 billion yuan, reflecting a year-on-year growth of 9.1% [6] - The fruit juice brand "Guolifang" under the Bottle Planet Group continues to show strong growth, with sales exceeding 10 million in four cities in the first half of the year [7] Group 3 - Sam's Club in Zhongshan is set to open in September, marking the first "Green Building Three-Star" Sam's store in the Greater Bay Area [7] - Walmart China celebrated the 29th anniversary of its first store opening, emphasizing its commitment to becoming the most trusted omnichannel retailer in China [6] - Taobao Hong Kong launched a limited-time "zero threshold" shipping promotion, allowing users to enjoy free shipping on single items without a minimum purchase requirement [10]

Core Viewpoint - The company, Health Road (02587.HK), will hold a board meeting on August 29, 2025, to review and approve its interim results for the six months ending June 30, 2025, and to consider the proposal for an interim dividend distribution, if any [1] Group 1 - The board meeting is scheduled for August 29, 2025 [1] - The meeting will focus on the interim results for the six months ending June 30, 2025 [1] - The company will also consider the proposal for an interim dividend distribution during the meeting [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內 容 概 不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不對因本公告全部或任何部份內容而產生或因倚賴該等內容而引致之 任 何 損 失 承 擔 任 何 責 任。 中 國 福 州，2025年8月13日 於 本 公 告 日 期，董 事 會 包 括 執 行 董 事 張 萬 能 先 生 及 陳 晶 先 生；非 執 行 董 事 章 向 明 先 生；及 獨 立 非 執 行 董 事 徐 景 先 生、Lu Tao博 士 及 鄧 曉 嵐 女 士。 董 健 康 之 路 股 份 有 限 公 司（「本公司」，連 同 其 附 屬 公 司 為「本集團」）董 事 會 （「董事會」）謹 此 宣 佈，董 事 會 會 議 將 於2025年8月29日（星 期 五）舉 行，以 審 議及批准本集團截至2025年6月30日 止 六 個 月 之 未 經 審 核 中 期 業 績，考 慮 是 否 宣 派 中 期 股 息 及 處 理 任 何 其 他 事 項。 代表董事會 健康之路股份有限公司 事 會 主 席、執 行 董 事 兼 行 政 總 裁 張 ...

Group 1 - The core viewpoint of the articles highlights the growth and innovation of the company "健康之路" (Health Road), which has established itself as a leading digital health service platform in China, leveraging AI technology to enhance healthcare services [1][2][4] - As of December 31, 2024, the platform boasts 889,000 registered doctors and 205 million registered personal users, indicating a vast user base that encourages more doctors to join, thereby improving service quality [1] - The company has developed various AI-driven platforms, such as the "AI援藏智慧医院平台" and "DIP智慧控费平台," which utilize AI and big data to enhance healthcare delivery and cost management [2] Group 2 - The company anticipates a profit of no less than 6 million yuan for the six months ending June 30, 2025, a significant turnaround from a loss of approximately 57.28 million yuan for the same period in 2024 [4] - The introduction of the "AI数字员工" (AI Digital Employee) system, which consists of a matrix of intelligent agents, is expected to improve service efficiency and reduce labor costs across various healthcare institutions [2] - Industry experts believe that the company is well-positioned to capitalize on the "AI + healthcare" market trend, potentially unlocking a second growth curve due to its extensive experience and resources accumulated over two decades in the digital healthcare sector [2]

Core Viewpoint - The company, Health Road (02587.HK), anticipates a profit of no less than RMB 6 million for the six months ending June 30, 2025, contrasting with a loss of approximately RMB 57.28 million for the same period in 2024, primarily due to changes in redeemable preference shares and listing expenses [1][2]. Financial Performance Summary - The expected revenue for the six months ending June 30, 2025, is projected to decrease by about 15% to 18% compared to the same period in 2024 [1]. - The gross profit for the six months ending June 30, 2025, is expected to decline by approximately 8% to 12% from the gross profit of RMB 183.66 million recorded for the six months ending June 30, 2024 [1]. Reasons for Revenue and Gross Profit Decline - The decrease in content service revenue is attributed to clients shifting to direct marketing strategies, reducing reliance on Real World Evidence (RWS) support services, and increased competition in the generic drug industry leading to budget cuts for RWS services [2]. - The decline in value-added medical service revenue is mainly due to the expiration of several sales agency agreements in 2025, ongoing negotiations for new agreements, and a proactive adjustment in service structure and classification [2]. - The reduction in digital marketing service revenue is linked to economic downturns prompting clients to cut advertising and marketing expenditures [2]. Company Overview - Health Road Co., Ltd. operates as a digital health service platform [3].

Group 1 - The company expects to record a profit of no less than RMB 6 million for the six months ending June 30, 2025, compared to a loss of approximately RMB 57.28 million for the same period in 2024 [1] - The anticipated loss in 2024 is primarily due to changes in the redemption liability value from the termination of the priority rights of convertible redeemable preferred shares and expenses incurred during the listing preparation [1] - Despite the expected profit, the company forecasts a revenue decrease of approximately 15% to 18% for the six months ending June 30, 2025, compared to the same period in 2024 [1] Group 2 - The board believes the expected decrease in revenue and gross profit is mainly due to a reduction in content service revenue, as some clients have shifted to direct marketing strategies, reducing reliance on Real World Evidence (RWS) support services [2] - Increased competition in the generic drug industry has led to a shift of resources towards commercialization, resulting in budget cuts for RWS services from some clients [2] - The decline in value-added medical services revenue is attributed to the expiration of several sales agency agreements in 2025 and ongoing negotiations for new agreements, along with a proactive adjustment in service structure and classification [2] - A decrease in digital marketing service revenue is primarily due to the economic downturn, prompting some clients to reduce advertising and marketing expenditures [2]

Core Viewpoint - The company expects to achieve a profit of no less than RMB 6 million for the six months ending June 30, 2025, contrasting with a loss of approximately RMB 57.28 million for the same period in 2024, primarily due to changes in redeemable preference shares and listing expenses [1] Group 1: Financial Performance - The company anticipates a revenue decrease of approximately 15% to 18% for the six months ending June 30, 2025, compared to the same period in 2024 [1] - The gross profit for the six months ending June 30, 2025, is expected to decrease by about 8% to 12% compared to a gross profit of approximately RMB 184 million for the six months ending June 30, 2024 [1] Group 2: Revenue Decline Factors - The anticipated revenue decline is mainly due to a reduction in content service revenue, as some clients are shifting to direct marketing strategies, reducing their reliance on Real World Evidence (RWS) support services [2] - The decrease in value-added medical services revenue is attributed to the expiration of several sales agency agreements in 2025 and ongoing negotiations for new agreements, along with a proactive adjustment in service structure leading to reduced income from comprehensive healthcare service packages [2] - Digital marketing service revenue is also expected to decline due to economic downturns prompting clients to cut advertising and marketing expenditures [2]

Core Viewpoint - The company expects to achieve a profit of at least RMB 6 million for the six months ending June 30, 2025, contrasting with a loss of approximately RMB 57.28 million for the same period in 2024, primarily due to changes in redeemable preference shares and listing expenses [1] Group 1: Financial Performance - The company anticipates a revenue decrease of approximately 15% to 18% for the six months ending June 30, 2025, compared to the same period in 2024 [1] - The gross profit for the six months ending June 30, 2025, is expected to decrease by about 8% to 12% compared to a gross profit of approximately RMB 184 million for the six months ending June 30, 2024 [1] Group 2: Revenue Decline Factors - The anticipated revenue decline is mainly due to a reduction in content service revenue, as some clients are shifting to direct marketing strategies, reducing their reliance on Real World Evidence (RWS) support services [2] - The decrease in value-added medical service revenue is attributed to the expiration of several sales agency agreements in 2025 and ongoing negotiations for new agreements, along with a proactive adjustment in service structure [2] - Digital marketing service revenue is expected to decline due to economic downturns, leading some clients to cut advertising and marketing expenditures [2]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內 容 概 不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不對因本公告全部或任何部份內容而產生或因倚賴該等內容而引致之 任 何 損 失 承 擔 任 何 責 任。 HealthyWay Inc. 健康之路股份有限公司 （於 開 曼 群 島 註 冊 成 立 之 有 限 公 司） （股 份 代 號：2587） 內幕消息 本 公 告 由 健 康 之 路 股 份 有 限 公 司（「本公司」，連 同 其 附 屬 公 司 統 稱「本 集 團」），根 據 香 港 聯 合 交 易 所 有 限 公 司 證 券 上 市 規 則（「上市規則」）第13.09(2) (a)條及香港法例第571章證券及期貨條例第XIVA部 之 內 幕 消 息 條 文（定 義 見 上 市 規 則）而 作 出。 本 公 司 董 事 會（「董事會」）謹 此 知 會 本 公 司 股 東 及 潛 在 投 資 者，根 據 董 事 會對本集團截至2025年6月30日止六個月的未經審核綜合管理賬目的初 步 審 閱 及 董 事 會 目 前 可 得 資 料，本 ...

Core Insights - The digital marketing in the pharmaceutical industry has transitioned from being an advanced trial for leading companies to a standard requirement for all pharmaceutical enterprises [1][16] - The importance of patient-centered digital marketing is increasing due to the reduction of information asymmetry between doctors and patients, heightened health awareness among patients, and increased participation in health solutions [1][2] - The market size for pharmaceutical digital marketing is steadily growing, but the capital enthusiasm has sharply declined since 2022, potentially due to differing definitions and value quantification methods of digital marketing [1][10] - Narrowly defined digital marketing merely refers to the online transition of traditional marketing, while true digital marketing encompasses the entire lifecycle of drug sales post-launch, integrating online and offline services driven by data [1][13] - The healthcare service chain is becoming more comprehensive, necessitating refined management of marketing services and more detailed quantifiable metrics, rather than a direct correlation with sales [1][14] Market Growth and Challenges - The pharmaceutical market in China is steadily increasing, with an average annual growth exceeding 100 billion [3] - Sales expenses of pharmaceutical companies are on the rise, with an average growth rate surpassing that of the overall pharmaceutical market [5] - Digital marketing budgets in biopharma companies have been increasing since 2019, but are expected to decline back to 2020 levels by 2024 [7][9] - The number of investment events in the pharmaceutical digital marketing sector saw a dramatic drop in 2022, following seven years of stable investment activity [10][12] Value Quantification Bottleneck - The future development of digital marketing is hindered by vague definitions and unquantified value, with narrow interpretations limiting the understanding of its potential [13] - True digital marketing should involve effective engagement with both doctors and patients, comprehensive service throughout the drug lifecycle, and integration of online and offline channels [13][14] - To achieve sales growth, effective information transfer across multiple marketing channels is essential, requiring a more granular assessment of marketing effectiveness [14][17] Evolving Marketing Needs - The evolution of the healthcare service chain has made digital marketing a necessity, with increased touchpoints requiring effective collaboration across various marketing channels [15][16] - The rise of digital platforms and the shift in patient information acquisition habits necessitate a robust online marketing strategy that complements offline efforts [15][16] - The demand for professional health management services and user-centered health content is growing, highlighting a gap in the market that needs to be addressed [21][22] Product Categories in Digital Marketing - Digital marketing products can be categorized into three types: tool-based, service-based, and solution-based [18] - Tool-based products focus on information technology solutions, while service-based products provide specialized health management services [19][21] - Solution-based products require a deeper understanding of user needs and aim to deliver comprehensive digital marketing strategies [26][27] Future Outlook - The digital marketing industry is expected to see more innovative players entering the market, enhancing the digital capabilities of tool-based products and improving service offerings [28] - Companies that can effectively integrate digital marketing solutions with a focus on patient-centered care will likely gain a competitive advantage [28]